

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/627,463	07/26/2003	Michel Koch	SERVIER 386 CIP	3244
25666	7590 02/09/2005		EXAM	INER
THE FIRM OF HUESCHEN AND SAGE			DELACROIX MUIRHEI, CYBILLE	
500 COLUME	BIA PLAZA			
350 EAST MICHIGAN AVENUE			ART UNIT	PAPER NUMBER
KALAMAZOO MI 40007			1614	· · · · · · · · · · · · · · · · · · ·

DATE MAILED: 02/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/627,463	KOCH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Cybille Delacroix-Muirheid	1614			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on 20 O	ctober 2004.				
<u> </u>	action is non-final.				
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) Claim(s) 1-15 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-15 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:				



Application/Control Number: 10/627,463

Art Unit: 1614

Detailed Action

The following is responsive to Applicant's amendment received Oct. 20, 2004.

No claims are cancelled. No new claims are added. Claims 1-15 are currently pending.

The previous claim objection set forth at paragraph 1 of the office action mailed Sep. 22, 2004 is withdrawn in view of Applicant's amendment and the remarks contained therein.

The previous claim rejection under 35 USC 112, second paragraph, set forth at paragraph 2 of the office action mailed Sep. 22, 2004 is withdrawn in view of Applicant's amendment and the remarks contained therein.

However, the following new ground(s) of rejection is respectfully submitted upon further consideration of the claims.

The indication of allowability of claims 1-6 and 8-12 is withdrawn.

New Ground(s) of Rejection

Claim Objection(s)

1. Claim 15 is objected to because of the following informalities: in claim 15, line 3, the Examiner respectfully submits that the "and" before "addition salts" should be deleted and replaced with –or--. Appropriate correction is required.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA

Application/Control Number: 10/627,463

Art Unit: 1614

1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1-15 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 16 of U.S. Patent No. 6,642,248 B2 in view of Khoo et al.

Claims 1 and 16 of USPN '248 recite a method for treating a living animal body afflicted with a cancer selected from leukemia and adenocarcinoma, the method comprising administering to the living animal body and effective amount of the compound described in claim 1.

Claims 1 and 16 do not specifically recite that a specific adenocarcinoma treated by the method is ovarian carcinoma. Yet, the Examiner refers to Khoo et al., which disclose the results of a study involving the treatment of patients suffering from ovarian cancer also known as <u>ovarian adenocarcinoma</u>. Please see the abstract; <u>Patients and Methods</u>.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the method of claim 16 to specifically treat ovarian adenocarcimona because Khoo et al. teach that ovarian carcinoma is a specific type of adenocarcinoma, i.e. a species within the generic term adenocarcinoma, and

Application/Control Number: 10/627,463

Art Unit: 1614

one of ordinary skill in the art would reasonably expect the compound of claim 1 to treat

ovarian carcinoma.

Conclusion

Claims 1-15 are rejected.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to **Cybille Delacroix-Muirheid** whose telephone number

is 571-272-0572. The examiner can normally be reached on Mon-Thurs. from 8:30 to

6:00 as well as every other Friday from 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Christopher Low, can be reached on 571-272-0951. The fax phone

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

CDM \(\int \mathbb{\chi} \mathbb{\chi} \)
Feb. 5, 2005

PAYMOND HEALEY III

Page 4

ALA 11014